Inovio Files 8-K on Bylaw Amendments; Governance Changes Ahead

TL;DR

**Inovio just filed an 8-K about changing its bylaws, watch for details on governance shifts.**

AI Summary

Inovio Pharmaceuticals, Inc. filed an 8-K on January 25, 2024, reporting an event from January 24, 2024, related to amendments to its Articles of Incorporation or Bylaws. This filing indicates a potential change in the company's corporate governance or structure, which could impact shareholder rights or future strategic decisions. For investors, understanding these changes is crucial as they might affect the company's operational flexibility or its ability to raise capital, potentially influencing stock valuation.

Why It Matters

This filing signals potential changes to Inovio's corporate rules, which could affect how the company is run, shareholder voting power, or future financial moves. Investors need to monitor these changes as they can impact the long-term value and stability of their investment.

Risk Assessment

Risk Level: medium — The filing indicates changes to corporate governance documents, which could have significant but currently unspecified impacts on shareholder rights or company operations, introducing uncertainty.

Analyst Insight

A smart investor would closely monitor Inovio's subsequent filings or announcements for the specific details of the amendments to its Articles of Incorporation or Bylaws, as these changes could significantly impact corporate governance and shareholder rights.

Key Players & Entities

• Inovio Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• January 24, 2024 (date) — date of the earliest event reported
• January 25, 2024 (date) — date the 8-K was filed
• 001-14888 (other) — Commission File Number for Inovio
• Delaware (other) — state of incorporation for Inovio

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark

Filing Documents

• d736726d8k.htm (8-K) — 27KB
• d736726dex31.htm (EX-3.1) — 6KB
• 0001193125-24-015380.txt ( ) — 158KB
• ino-20240124.xsd (EX-101.SCH) — 3KB
• ino-20240124_lab.xml (EX-101.LAB) — 18KB
• ino-20240124_pre.xml (EX-101.PRE) — 11KB
• d736726d8k_htm.xml (XML) — 3KB

03

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 24, 2024, Inovio Pharmaceuticals, Inc. (the " Company ") filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended (the " Charter Amendment ") to effect a 1-for-12 reverse stock split of the Company's common stock (the " Reverse Stock Split "). The Reverse Stock Split became effective at 5:00 p.m. Eastern Time on January 24, 2024. As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The par value per share of the common stock remained unchanged at $0.001. Fractional shares were not issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive a fractional share received a proportional cash payment based on the closing price of the common stock on the Nasdaq Capital Market on January 24, 2024. The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. The Reverse Stock Split did not reduce the number of authorized shares of the Company's common stock, which remains at 600,000,000. The foregoing summary is qualified in its entirety by reference to the Charter Amendment, which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Certificate of Incorporation of Inovio Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Inovio Pharmaceuticals, Inc. Dated: January 25, 2024 By: /s/ Peter Kies Peter Kies Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR